Stemcell United Ltd. (AU:BP8)
ASX:BP8
Top Page
Stemcell United Ltd.
(Sydney:BP8)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
▲(384.62% Upside)
Action:N/ADate:01/04/26
The score is primarily weighed down by weak financial performance: persistent losses, negative equity, and ongoing cash burn despite recent revenue growth. With technical and valuation inputs largely unavailable, the overall result remains cautious due to limited evidence of improving fundamentals.
Stemcell United Ltd. (BP8) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.71M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.72
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees31
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,353,484,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)3.20
P/FCF Ratio-1.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Stemcell United Ltd. Business Overview & Revenue Model
Company Description
BPH Global Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's ne...
How the Company Makes Money
null...
Stemcell United Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 352.38K | 109.97K | 339.00 | 14.35M | 8.50M |
| Gross Profit | -678.01K | 18.27K | 339.00 | 2.29M | 1.54M |
| EBITDA | -1.45M | -1.76M | -2.49M | -2.49M | -2.41M |
| Net Income | -1.49M | -2.27M | -4.32M | -3.54M | -3.13M |
Balance Sheet | |||||
| Total Assets | 541.00K | 691.84K | 2.10M | 7.16M | 10.11M |
| Cash, Cash Equivalents and Short-Term Investments | 152.74K | 134.82K | 1.14M | 685.56K | 5.26M |
| Total Debt | 0.00 | 508.64K | 0.00 | 1.30M | 1.76M |
| Total Liabilities | 2.01M | 1.97M | 1.19M | 2.44M | 3.83M |
| Stockholders Equity | -1.45M | -966.82K | 530.13K | 3.20M | 5.26M |
Cash Flow | |||||
| Free Cash Flow | -932.18K | -1.26M | -1.49M | -4.93M | -1.78M |
| Operating Cash Flow | -929.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -2.37K | 185.33K | 6.29K | -914.21K | -418.04K |
| Financing Cash Flow | 962.99K | 697.04K | 1.38M | 281.27K | 6.25M |
Stemcell United Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$4.71M | -0.76 | 95.35% | ― | ― | ― | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
43 Neutral | AU$3.38M | -0.33 | 346.27% | ― | 5.52% | 49.25% | |
43 Neutral | AU$11.21M | -1.00 | -218.76% | ― | ― | ― | |
43 Neutral | AU$9.81M | -1.61 | 142.99% | ― | -47.02% | 94.37% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% |
* Healthcare Sector Average
AU:BP8
Stemcell United Ltd.
―
―
―
AU:OSX
Osteopore Ltd.
0.01
-0.02
-66.67%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
AU:1AD
AdAlta Ltd.
―
―
―
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:IBX
Imagion Biosystems Ltd.
0.02
0.01
76.92%
Stemcell United Ltd. Corporate Events
BPH Global targets seaweed-based biofuel as fermentation business nears commercial stage
Mar 16, 2026
BPH Global Ltd. has expanded its seaweed biomass research program to pursue renewable biofuel production alongside its existing nutraceutical focus. By fermenting seaweed, the company already produces biohydrogen and biomethane as by-products and ...
BPH Global outlines seaweed biotech positioning in investor briefing
Mar 16, 2026
BPH Global Limited has released an investor presentation outlining information about its seaweed biotechnology business and its positioning as an emerging player in this niche sector. The document emphasises that it is purely informational, does n...
BPH Global Lifts Capital Base as Seasonal Headwinds Temper Seaweed Sales
Feb 22, 2026
BPH Global Ltd, an ASX-listed seaweed trader operating out of Makassar in Indonesia, sources product from local coastal farmers to supply domestic and export markets, including customers across Asia. The company is building an independent trading ...
Apertus Capital Ceases to Be Substantial Holder in BPH Global After Share Issue
Feb 20, 2026
Apertus Capital Pty Ltd has filed a notice that it has ceased to be a substantial shareholder in BPH Global Ltd following dilution arising from a share issue. The filing indicates that Apertus now has no voting power in BPH Global, and that there ...
Stemcell United Loses ATIDIM as Substantial Shareholder After Share Issue
Feb 20, 2026
Stemcell United Ltd. has disclosed that ATIDIM Investments Pty Ltd and associated holder BPH Global Ltd have ceased to be substantial shareholders in the company following dilution from a new share issue. The notice indicates that ATIDIM’s v...
BPH Global Secures BRIN Partnership to Advance Fucoidan-Based Anti-Ageing Products
Feb 6, 2026
BPH Global Ltd’s Indonesian subsidiary, PT BPH Global Indonesia, has signed a binding Memorandum of Understanding with Indonesia’s National Research and Innovation Agency (BRIN) under the government’s “BRIN Goes to Industri...
BPH Global Plans Issue of 150 Million Options to Support Capital Needs
Feb 4, 2026
BPH Global Ltd has lodged a notice of a proposed securities issue with the ASX, outlining plans to issue up to 150 million new options as part of a placement or similar capital-raising mechanism. The options will carry an exercise price of $0.004 ...
BPH Global Plans Major Share and Option Issue to Boost Capital Base
Feb 4, 2026
BPH Global Ltd, listed on the ASX under code BP8, is an Australia-registered company; the announcement does not specify its industry, products, or market focus. The company has notified the ASX of a proposed capital raising via the issue of up to ...
BPH Global Raises $1m to Accelerate Growth of Indonesian Seaweed Platform
Feb 4, 2026
BPH Global has secured firm commitments for a $1 million strategic share placement at market price, introducing new long-term investors and bolstering its balance sheet as its Indonesian seaweed operations record their strongest and second-stronge...
BPH Global Requests Trading Halt Ahead of Capital Raising Announcement
Feb 2, 2026
BPH Global Ltd, listed on the ASX under the ticker BP8, has requested a trading halt in its securities as it prepares an announcement regarding a capital raising. Trading in BPH Global shares will be paused until either the start of normal trading...
BPH Global Relocates Registered Office to New Melbourne Address
Feb 2, 2026
BPH Global Ltd has announced a change to its registered office address, relocating its corporate headquarters to Suite 303, 365 Little Collins Street in Melbourne, Victoria, effective 2 February 2026. The move represents an administrative update w...
BPH Global Completes Capital Raising as Indonesian Seaweed Operations Hit Record Sales
Jan 30, 2026
BPH Global has reported its December quarter activities, highlighting completion of the second tranche of a capital raising of up to A$1.1 million through the issue of 550 million shares with attached options, following shareholder approval in Nov...
BPH Global Confirms Metal-Rich Sediments in Johor River Ahead of Seaweed Bio-Accumulation Trials
Jan 20, 2026
BPH Global Ltd has reported significant assay results from riverbed soil samples collected at two freshwater sites in Malaysia’s Johor River, with measurable concentrations of copper, silver and selected rare earth elements, including lantha...
BPH Global Launches R&D to Turn Non-Export Seaweed into Animal Feed Inputs
Jan 12, 2026
BPH Global Ltd has launched a low-risk research and development program to evaluate the use of non-export grade Eucheuma cottonii seaweed in animal feed and feed supplement applications, aiming to utilise biologically active material that falls ou...
BPH Global Refocuses Seaweed R&D on Gold and Silver Recovery
Jan 7, 2026
BPH Global Ltd has finalised an updated 2026–2027 RD program under its “Project 6–7,” sharpening its focus on measuring, extracting and commercially recovering gold and silver from seaweed biomass. Following internal and ex...
BPH Global’s December Seaweed Revenue Hit by Seasonal Rains but Growth Plans Intact
Dec 30, 2025
BPH Global reported gross revenue of IDR 1.88 billion (about A$171,000) for the December trading period, bringing total sales since commencing operations in mid-May to roughly A$1.77 million as the company continues to build its Indonesian seaweed...
BPH Global Options Lapse as 1 Million BP8AA Securities Expire Unexercised
Dec 24, 2025
BPH Global Ltd, listed on the ASX under ticker BP8, has reported a change in its issued capital structure following the expiry of certain options. The company announced that 1,000,000 BP8AA options, which were due to expire on various dates and at...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.